Compare ABVX & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABVX | HIMS |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Nursing Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.9B |
| IPO Year | N/A | N/A |
| Metric | ABVX | HIMS |
|---|---|---|
| Price | $116.42 | $31.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 13 |
| Target Price | ★ $130.09 | $43.82 |
| AVG Volume (30 Days) | 2.0M | ★ 13.7M |
| Earning Date | 08-11-2025 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.76 |
| EPS | N/A | ★ 0.54 |
| Revenue | $6,231,374.00 | ★ $2,210,958,000.00 |
| Revenue This Year | $6.80 | $62.27 |
| Revenue Next Year | N/A | $18.20 |
| P/E Ratio | ★ N/A | $58.45 |
| Revenue Growth | N/A | ★ 78.02 |
| 52 Week Low | $4.77 | $23.97 |
| 52 Week High | $148.83 | $72.98 |
| Indicator | ABVX | HIMS |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 36.52 |
| Support Level | $113.40 | $29.92 |
| Resistance Level | $130.13 | $33.27 |
| Average True Range (ATR) | 8.75 | 1.63 |
| MACD | -1.95 | -0.09 |
| Stochastic Oscillator | 19.84 | 23.74 |
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.